The year of 2024 marks the beginning of a new journey for us. We have revised our mid-term management plan from 2021 to 2023 and established a new three-year plan.
In a global landscape characterized by increasing diversity, division, and geopolitical risk, coupled with volatility in interest rates and foreign exchange markets, the business environment is fraught with unprecedented uncertainty.
In response to these challenges, we recognize the need for a dynamic and multi-faceted strategy to effectively navigate the future.
In biotechnology, our commitment is unwavering. We are deeply involved in research and development, licensing agreements, and mergers and acquisitions. Our focus spans a range of medical concerns, including cancer and genetic disorders, while embracing new modalities and the transformative potential of digital technology. Despite the prevailing trend of drug price reductions in Japan, we are witnessing a paradigm shift as pharmaceutical and biotech companies, both domestic and international, embark on novel alliances and collaborations.
In line with these evolving industry dynamics, we have created a new "Mission, Vision and Values". Our redefined mission - "We brighten people's lives through the power of innovation" - reflects our commitment to making a meaningful impact. Our goal is to build strong relationships with all stakeholders and maximize shareholder value.
Your trust and partnership are invaluable as we strive to achieve our shared goals.
We sincerely ask for your continued understanding and support as we embark on this exciting new chapter.
President&CEO Hirobumi Takeuchi